MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-14-2022
CASI Pharmaceuticals Revenue 2011-2026 | CASI
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue CASI Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 30.2 M | 15.1 M | 4.13 M | - | - | - | 47.7 K | 23.7 K | - | 669 K | 1.94 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 30.2 M | 23.7 K | 7.45 M |
Quarterly Revenue CASI Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 10.2 M | 8.57 M | 9.06 M | - | 8.11 M | 7.16 M | 5.74 M | - | 4.24 M | 2.67 M | 3.41 M | - | 2.79 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 24 K | 23.7 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.85 K | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 10.2 M | 8.85 K | 4.77 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M |  Germany |
 |
Adagene
ADAG
|
10.2 M | $ 1.68 | 1.9 % | $ 94.6 M |  China |
 |
Aptorum Group Limited
APM
|
912 K | $ 1.08 | -0.19 % | $ 5.89 M | China |
 |
Arrowhead Pharmaceuticals
ARWR
|
829 M | $ 65.3 | 0.46 % | $ 8.73 B |  USA |
 |
Ascendis Pharma A/S
ASND
|
364 M | $ 210.55 | 0.86 % | $ 5 B |  Danmark |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | USA |
 |
Alterity Therapeutics Limited
ATHE
|
109 K | $ 3.41 | 2.4 % | $ 8.2 B |  Australia |
 |
AgeX Therapeutics
AGE
|
142 K | - | -10.17 % | $ 12.2 K | USA |
 |
Autolus Therapeutics plc
AUTL
|
242 K | $ 1.86 | -2.62 % | $ 475 M |  Britain |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
Albireo Pharma
ALBO
|
40.6 M | - | -0.23 % | $ 916 M | USA |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M | Britain |
 |
Alpine Immune Sciences
ALPN
|
30.1 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
165 K | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
1.16 M | - | -11.43 % | $ 502 K | USA |
 |
Aravive
ARAV
|
9.14 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
54 K | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
5.51 M | - | 3.77 % | $ 22.4 M | USA |
 |
Biogen
BIIB
|
9.68 B | $ 187.47 | 0.79 % | $ 27.3 B | USA |
 |
AIkido Pharma
AIKI
|
18.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - |  Russia |
 |
Acasti Pharma
ACST
|
100 M | - | 4.01 % | $ 150 M |  Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
60.3 M | - | -15.15 % | $ 60.3 M | Britain |
 |
BioNTech SE
BNTX
|
482 M | $ 100.15 | 1.31 % | $ 27.2 B | Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
732 M | $ 27.62 | -0.43 % | $ 1.34 B | USA |
 |
BioXcel Therapeutics
BTAI
|
2.27 M | $ 1.98 | -1.0 % | $ 5.02 M | USA |
 |
CureVac N.V.
CVAC
|
48.9 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
1.26 M | - | 2.71 % | $ 14 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
463 M | $ 11.85 | 4.45 % | $ 766 M | USA |
 |
BioDelivery Sciences International
BDSI
|
167 M | - | -4.8 % | $ 255 M | USA |
 |
Axon Enterprise
AXON
|
2.08 B | $ 629.67 | 2.72 % | $ 47.7 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
692 K | - | - | $ 7.46 M |  Israel |
 |
Aytu BioScience
AYTU
|
66.4 M | $ 2.65 | -0.38 % | $ 16.6 M | USA |
 |
BeiGene, Ltd.
BGNE
|
3.81 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
AstraZeneca PLC
AZN
|
54.1 B | $ 95.16 | 1.22 % | $ 96.9 B | Britain |
 |
Bellicum Pharmaceuticals
BLCM
|
1.5 M | - | -9.72 % | $ 5.89 M | USA |
 |
Acorda Therapeutics
ACOR
|
118 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
8.01 M | - | -5.38 % | $ 6.06 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
853 K | $ 4.17 | -3.02 % | $ 9.07 B | Israel |
 |
Burford Capital Limited
BUR
|
330 M | $ 9.34 | 0.59 % | $ 1.52 B | Britain |
 |
Catalyst Biosciences
CBIO
|
113 M | $ 10.92 | -0.46 % | $ 719 M | USA |
 |
Berkeley Lights
BLI
|
78.6 M | - | -7.31 % | $ 87 M | USA |